Resources

AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 865

The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an
independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention
was safe and highly effective against HIV. No infections were seen among trial participants those receiving LEN. This advocates’ primer provides further background on the product and trials, raises key questions, and explores next steps.

Prevention Option:

July 2024


Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Injectable Lenacapavir for PrEP

A global cadre of HIV prevention advocates is calling for an accelerated timeline for access to the HIV prevention drug lenacapavir. Gilead, the developer of the drug, announced topline results from a large study among cisgender African women on 20 June, followed shortly thereafter with a statement about access.

Prevention Option:

July 2024


GPP Body of Evidence Webinar Series

Good Participatory Practice Guidelines have been shaping and improving clinical research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.

Prevention Option:

July 2024


STI Watch Newsletter, July 2024

In the second quarter of this year, there have been exciting new reports and updates on guidelines that could help better inform our efforts and ultimately reduce STIs.

July 2024


PrEP in Black America (PIBA) and Black Public Health Academy Share Statement on Lenacapavir Results

PrEP in Black America (PIBA) and Black Public Health Academy share statement on results of twice-a-year infectable lenacapavir for PrEP proving efficacious among African cisgender women and what this means for Black communities in the US.

July 2024


From The Lab To The Jab: Lessons learned and what’s next in HIV vaccine research

On 3 June 2024, AVAC hosted a webinar highlighting its Lab to Jab issue briefs on research and development, production and equitable global access to vaccines. Platforms, Not Pathogens Panelists stressed an intentional, rather than incidental...

June 2024


An Overview of Lenacapavir for PrEP Trials

The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1.

Prevention Option:

June 2024


Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective

Adding additional HIV prevention options means more people may find an option that is right for them. Beyond expanded choice, a twice-yearly injection has the potential to transform the way we deliver HIV prevention to people who need and want it most.

June 2024


Advocates’ Guide to Doxycycline to Prevent Bacterial STIs (DoxyPEP)

DoxyPEP is a post-exposure prophylaxis used to prevent the acquisition of some bacterial STIs after sex. DoxyPEP is inexpensive, easily tolerated, and widely available. However, questions remain regarding who will benefit most from DoxyPEP and how to implement this strategy broadly to ensure equitable access.

June 2024


Advocates’ Guide for PPPR

If you’re having trouble making sense of all of the initiatives around pandemic prevention, preparedness, and response (PPPR) this year, don’t worry—you’re not alone! This Advocates Guide provides a reference for the relevant information all in one place. The contents explain the major initiatives, key dates for involvement, how to get involved and make sure your priorities are heard by decision makers.

Prevention Option:

June 2024


showing 1-10 of 865